secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001683168-26-003432
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharma raises ~$22.5M in private placement at $2.30/sh; board change
------------------------------------------------------------------------

- Gross proceeds ~$22.5M from sale of 650K shares at $2.30/sh and pre-funded warrants for 9.14M shares at $2.299/warrant.
- Proceeds to identify, acquire, advance new assets and for working capital.
- Director Jerzy Gumulka resigns (no disagreement); Michal Fisher appointed independent director.
- 120-day lock-up on equity sales after registration effective; no variable rate transactions for one year.
- Placement agent A.G.P./Alliance Global Partners receives 7% cash fee plus up to $90K expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316826003432/0001683168-26-003432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316826003432/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-003432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer